tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IDYA Stock Latest News

Ideaya Biosciences price target raised to $79 from $74 at JPMorgan
The FlyIdeaya Biosciences price target raised to $79 from $74 at JPMorgan
7h ago
IDYA
Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs
PremiumThe Fly
Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs
2d ago
IDYA
Ideaya Biosciences price target raised to $41 from $38 at RBC Capital
PremiumThe Fly
Ideaya Biosciences price target raised to $41 from $38 at RBC Capital
2d ago
IDYA
Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
PremiumRatings
Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
3d ago
IDYA
IDEAYA Biosciences Presents Promising Phase 2 Data
PremiumCompany Announcements
IDEAYA Biosciences Presents Promising Phase 2 Data
3d ago
8K
IDYA
IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating
PremiumRatingsIDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating
3d ago
IDYA
Ideaya Biosciences presents clinical data from OptimUM-09 trial
Premium
The Fly
Ideaya Biosciences presents clinical data from OptimUM-09 trial
3d ago
IDYA
Ideaya Biosciences reports overall survival data from darovasertib trial
Premium
The Fly
Ideaya Biosciences reports overall survival data from darovasertib trial
3d ago
PFE
IDYA
Promising Potential of IDEAYA Biosciences: Strong Efficacy and Financial Stability Support Buy Rating
PremiumRatings
Promising Potential of IDEAYA Biosciences: Strong Efficacy and Financial Stability Support Buy Rating
6d ago
IDYA
IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating
PremiumRatings
IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating
15d ago
IDYA
Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors
PremiumCompany Announcements
Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors
27d ago
IDYA
Promising Developments in IDEAYA Biosciences’ Pipeline Drive Buy Rating with $74 Price Target by 2026
PremiumRatings
Promising Developments in IDEAYA Biosciences’ Pipeline Drive Buy Rating with $74 Price Target by 2026
28d ago
IDYA
JPMorgan places ‘Positive Catalyst Watch’ on Ideaya into updates
PremiumThe FlyJPMorgan places ‘Positive Catalyst Watch’ on Ideaya into updates
28d ago
IDYA
Ideaya Biosciences initiated with a Buy at Guggenheim
Premium
The Fly
Ideaya Biosciences initiated with a Buy at Guggenheim
1M ago
IDYA
Ideaya Biosciences initiated with a Buy at Guggenheim
Premium
The Fly
Ideaya Biosciences initiated with a Buy at Guggenheim
1M ago
IDYA
Ideaya Biosciences price target raised to $44 from $43 at Mizuho
PremiumThe Fly
Ideaya Biosciences price target raised to $44 from $43 at Mizuho
1M ago
IDYA
IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
PremiumRatings
IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
1M ago
IDYA
Ideaya Biosciences price target raised to $38 from $36 at RBC Capital
PremiumThe Fly
Ideaya Biosciences price target raised to $38 from $36 at RBC Capital
1M ago
IDYA
Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst
PremiumRatings
Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst
1M ago
IDYA
Ideaya should be bought on yesterday’s selloff, says Wells Fargo
PremiumThe FlyIdeaya should be bought on yesterday’s selloff, says Wells Fargo
1M ago
IDYA
Ideaya Biosciences selloff on R&D day overdone, says Citi
Premium
The Fly
Ideaya Biosciences selloff on R&D day overdone, says Citi
1M ago
IDYA
IDEAYA Biosciences: Promising Pipeline and Clinical Advancements Drive Buy Rating
Premium
Ratings
IDEAYA Biosciences: Promising Pipeline and Clinical Advancements Drive Buy Rating
1M ago
IDYA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >